Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Parkinson disease

Intestinal levodopa infusion in PD—the first randomized trial

Nature Reviews Neurology volume 10, pages 128–129 (2014)Cite this article

Subjects

The first randomized, placebo-controlled trial of intrajejunal levodopa provides support for the benefits of continuous dopaminergic drug delivery. Motor fluctuations in patients with advanced Parkinson disease were markedly improved. In clinical practice, the symptomatic benefits of this treatment need to be weighed carefully against its adverse effect profile.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Olanow, C. W. et al. Continuous intrajejunal infusion of levodopa–carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 13 141–149 (2014).

    Article  CAS  PubMed  Google Scholar 

  2. Olanow, C. W., Obeso, J. A. & Stocchi, F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 5, 677–687 (2006).

    Article  CAS  PubMed  Google Scholar 

  3. Nutt, J. G. Pharmacokinetics and pharmacodynamics of levodopa. Mov. Disord. 23 (Suppl. 3), S580–S584 (2008).

    Article  PubMed  Google Scholar 

  4. Fox, S. H. et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 26 (Suppl. 3), S2–S41 (2011).

    Article  PubMed  Google Scholar 

  5. Deuschl, G. & Agid, Y. Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits. Lancet Neurol. 12, 1025–1034 (2013).

    Article  PubMed  Google Scholar 

  6. Wirth, R. et al. Complications and mortality after percutaneous endoscopic gastrostomy in geriatrics: a prospective multicenter observational trial. J. Am. Med. Dir. Assoc. 13, 228–233 (2012).

    Article  PubMed  Google Scholar 

  7. Richter-Schrag, H. J. et al. Risk factors and complications following percutaneous endoscopic gastrostomy: a case series of 1041 patients. Can. J. Gastroenterol. 25, 201–206 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Toth, C. et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann. Neurol. 69, 28–36 (2010).

    Article  Google Scholar 

  9. Fernandez, H. H. et al. Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat. Disord. 19, 339–345 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Müller, T. et al. Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat. Disord. 19, 501–507 (2013).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Danube Hospital, Langobardenstrasse 122, Vienna, 1220, Austria

    Regina Katzenschlager

  2. Department of Neurology, Innsbruck Medical University, Anichstrasse 35, Innsbruck, 6020, Austria

    Werner Poewe

Authors
  1. Regina Katzenschlager
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Werner Poewe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Regina Katzenschlager.

Ethics declarations

Competing interests

R.K. has received research funding from Novartis, Bial and Schering-Plough. Both authors have received consultancy fees and lecture fees in relation to clinical drug development programmes for Parkinson disease from Abbvie and Novartis. In addition, R.K. has received fees for consultancy and lectures from AOP Orphan, Biogen, Britannia, Ever Pharma, Lundbeck, Stada and UCB, and W.P. has received fees for consultancy and lectures from Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Serono, Merz Pharmaceuticals, Orion Pharma, Teva and UCB.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Katzenschlager, R., Poewe, W. Intestinal levodopa infusion in PD—the first randomized trial. Nat Rev Neurol 10, 128–129 (2014). https://doi.org/10.1038/nrneurol.2014.26

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2014.26

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing